Stimwave Technologies announced that the Food and Drug Administration (FDA) has granted clearance to market the Stimwave Freedom Spinal Cord Stimulation (SCS) System, the first wireless, microtechnology neuromodulation device for chronic back and leg pain relief.
The Stimwave SCS System utilizes a tiny injectable microchip device that sends small pulses of energy to electrodes near surrounding nerves. This elicits a reaction that allows the remapping of specific pain signals, thus resulting in pain relief.
The device measures between 2–11cm and can be implanted through a standard needle. It eliminates the use of long wires that would normally be inserted through the body and connected to a battery source with other neuromodulation devices. The Stimwave device does not contain any internal batteries or other toxic materials. It is permanently set in place by an anchor and moves in line with the body’s nerves for more freedom of motion. Further, the patient is able to undergo a whole body 3T or 1.5T MRI without having to removing the implant.
The Stimwave Freedom SCS System will be available in January 2015.
For more information call (800) 965-5134 or visit Stimwave.com.